Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Luvadaxistat · NBI-1065844, TAK-831

Small molecule · developed by NEUROCRINE BIOSCIENCES

Phase 2 Most advanced trial (none active)
NBIX Developer
1 Registered trials

What is Luvadaxistat?

Luvadaxistat is an investigational small-molecule drug studied in Schizophrenia.

At a glance

Also known as
NBI-1065844, TAK-831
Drug type
Small molecule
Therapy area
Psychiatry
Developer
NEUROCRINE BIOSCIENCES (NBIX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
76IC00YRVR

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05182476 Phase 2 Schizophrenia Terminated NBIX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Schizophrenia

More from NEUROCRINE BIOSCIENCES

Crinecerfont FDA approved Valbenazine FDA approved Chronocort Phase 3 DITEST Phase 1 NBI-1065845 Phase 3 NBI-1065890 Phase 2 NBI-1070770 Phase 2 NBI-1117567 Phase 2 NBI-1117568 Phase 3 NBI-1117570 Phase 2 NBI-827104 Phase 2 NBI-921352 Phase 2

Follow NBIX, the company behind Luvadaxistat

See NBIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NBIX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.